The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells
Open Access
- 2 August 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (40) , 68591-68598
Abstract
The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cellsKeywords
This publication has 31 references indexed in Scilit:
- Epigenetics in human gliomasCancer Letters, 2014
- Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade GliomasCancer Cell, 2013
- Understanding high grade glioma: Molecular mechanism, therapy and comprehensive managementCancer Letters, 2013
- Expression and significance of histone H3K27 demethylases in renal cell carcinomaBMC Cancer, 2012
- A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage responseNature, 2012
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastomaNature, 2012
- Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancersNature Reviews Cancer, 2010
- Malignant Gliomas in AdultsNew England Journal of Medicine, 2008
- H3K27 Demethylases, at Long LastCell, 2007
- Epidemiology and molecular pathology of gliomaNature Clinical Practice Neurology, 2006